Subcutaneous Model
In Vivo Services
Subcutaneous Model Overview
The subcutaneous tumor model is one of the most commonly used in vivo evaluation systems for assessing the efficacy of novel anti-cancer drugs. Typically, tumor cells are implanted subcutaneously into the flank or back of animals, primarily mice. In these locations, the transplanted cells proliferate and develop into measurable tumors. This model is favored for its convenience and minimally invasive process, with minimal impact on animals during longitudinal monitoring. KYINNO maintains a repository of more than 3000 tumor cell lines and has established a variety of subcutaneous tumor models, including traditional CDX models, BaF3 xenograft models, Syngeneic Models, Gene-editing Xenograft models, Luciferase Tumor Models, and more, thanks to our extensive cell bank resources.
All in vivo Services
Ba/F3 Xenograft focuses on protein kinases, a cornerstone in cancer research. With FDA’s acknowledgment of kinase drugs, it offers important oncology insights aiding for deeper understanding.
Gene-edited xenografts, utilizing tools like CRISPR/Cas9, offer precise modifications to tumor cell genomes, significantly expanding the horizons and potential of modern oncological research methodologies and insights.
Luciferase tumor model provides insights into tumor growth and immune dynamics. Using bioluminescence, it provides real-time insights. This innovative approach deepens comprehension, advancing cancer research and promoting novel therapeutic discoveries.
PBMC Humanized Mouse Model incorporates human T cells’ behavior, enabling detailed tumor immunology analysis. It presents a unique avenue for in-depth exploration, enriching research and offering a comprehensive study platform.
The Syngeneic Model leverages the uses of mouse-derived tumor tissues, placed into genetically similar hosts, contributing to consistency and depth in cancer studies. Ensures a genuine environment for cancer study.
The Subcutaneous tumor models are a leading choice for evaluating anti-cancer drug efficacy, supporting clinical trials, and understanding potential treatments. Its established method is a key component in therapeutic research.
The subcutaneous tumor model is one of the most commonly used in vivo evaluation systems for assessing the efficacy of novel anti-cancer drugs. Typically, tumor …
The CDX Model utilizes human tumor cells cultured and introduced into immunodeficient mice, providing a distinct perspective in cancer research.This approach offers a unique, in-depth exploration into cancer behaviors.
